Three major clinical trials have introduced personalized treatment options for ovarian cancer that stops responding to platinum chemotherapy. Mirvetuximab soravtansine targets tumors with high folate receptor alpha expression, pembrolizumab combined with paclitaxel helps patients with specific immune markers, and relacorilant with nab-paclitaxel works without requiring tumor testing. According to Gram Research analysis, treatment should be customized based on each patient’s tumor characteristics, prior treatments, and individual needs rather than following one fixed approach for everyone.
According to Gram Research analysis, three major clinical trials have changed how doctors treat ovarian cancer that stops responding to standard platinum chemotherapy. These trials introduced three new treatment approaches: mirvetuximab soravtansine for tumors with high folate receptor alpha, pembrolizumab combined with paclitaxel for tumors with specific immune markers, and relacorilant with nab-paclitaxel for selected patients. Rather than following one fixed treatment plan for everyone, doctors can now personalize treatment based on each patient’s tumor characteristics, previous treatments, and individual needs. This review helps clinicians understand how to sequence these new options for better outcomes.
Key Statistics
A 2026 narrative review in the International Journal of Women’s Health analyzed three Phase III trials (MIRASOL, KEYNOTE-B96, and ROSELLA) that established three distinct evidence-based treatment approaches for platinum-resistant epithelial ovarian cancer, moving beyond historical single-agent chemotherapy with limited durability.
The MIRASOL trial established mirvetuximab soravtansine as an effective folate receptor alpha-targeted therapy for assay-defined FRα-positive platinum-resistant ovarian cancer, enabling biomarker-directed treatment selection for this patient population.
KEYNOTE-B96 demonstrated that pembrolizumab combined with weekly paclitaxel improves outcomes in PD-L1 CPS-positive platinum-resistant recurrent epithelial ovarian cancer, providing an immunotherapy-based sequencing option for eligible patients.
ROSELLA showed that relacorilant with nab-paclitaxel improves treatment activity in platinum-resistant ovarian cancer without requiring conventional tumor biomarker testing, expanding treatment access to patients selected by clinical criteria.
The Quick Take
- What they studied: How three new clinical trials (MIRASOL, KEYNOTE-B96, and ROSELLA) should change the way doctors treat ovarian cancer that no longer responds to platinum-based chemotherapy.
- Who participated: This is a review article analyzing results from three major clinical trials involving patients with platinum-resistant epithelial ovarian cancer. The review synthesizes evidence to guide treatment decisions for this patient population.
- Key finding: Three distinct new treatment approaches now offer personalized options based on tumor characteristics: targeted antibody-drug therapy for specific tumor markers, immunotherapy combined with chemotherapy for immune-responsive tumors, and a new drug that works without requiring tumor testing.
- What it means for you: If you or a loved one has ovarian cancer that stopped responding to standard chemotherapy, doctors now have more targeted treatment options. Treatment can be customized based on your tumor’s specific characteristics and your medical history, potentially improving outcomes and reducing side effects. Discuss these options with your oncologist to determine which approach is best for your situation.
The Research Details
This is a narrative review article that examines and synthesizes findings from three major Phase III clinical trials published between 2024-2026. The authors analyzed how results from MIRASOL, KEYNOTE-B96, and ROSELLA trials should inform treatment decisions for patients with platinum-resistant epithelial ovarian cancer—a condition where tumors stop responding to platinum-based chemotherapy drugs.
The review takes a comprehensive approach by evaluating each trial’s evidence separately, then discussing how these different treatment options can be sequenced and combined for individual patients. Rather than declaring one treatment as universally best, the authors emphasize that optimal treatment selection requires considering multiple factors specific to each patient.
This type of review is valuable because it helps translate complex clinical trial results into practical guidance that doctors can use in everyday patient care. The authors examine not just whether treatments work, but how to choose between them based on tumor characteristics, prior treatments, side effect risks, and patient preferences.
This review matters because it addresses a critical gap in cancer care. Patients with platinum-resistant ovarian cancer historically had very limited options with poor outcomes. By synthesizing evidence from three major trials, this review helps oncologists move beyond one-size-fits-all treatment approaches to personalized medicine. Understanding how to sequence these new treatments based on individual patient factors can improve survival, reduce unnecessary side effects, and help patients maintain quality of life during treatment.
This is a narrative review published in a peer-reviewed journal, which means it has undergone expert evaluation. The authors base their analysis on Phase III randomized controlled trials—the gold standard for clinical evidence. However, as a review article rather than a new research study, it synthesizes existing evidence rather than generating new data. The strength of the recommendations depends on the quality of the underlying trials (MIRASOL, KEYNOTE-B96, and ROSELLA), which are major Phase III studies. Readers should note that treatment recommendations in oncology evolve as new evidence emerges, so discussing options with your medical team is essential.
What the Results Show
The MIRASOL trial established that mirvetuximab soravtansine—a targeted antibody-drug conjugate that attacks folate receptor alpha on tumor cells—is effective for patients whose tumors have high folate receptor alpha expression. This represents a major advance because it allows doctors to select patients most likely to benefit based on a specific tumor characteristic.
The KEYNOTE-B96 trial demonstrated that adding pembrolizumab (an immunotherapy drug) to weekly paclitaxel chemotherapy, with or without bevacizumab, improves outcomes in patients whose tumors have a specific immune marker called PD-L1. This approach harnesses the immune system to fight cancer while also delivering chemotherapy.
The ROSELLA trial showed that relacorilant—a drug that blocks glucocorticoid receptors—improves the effectiveness of nab-paclitaxel chemotherapy in selected patients. Notably, this approach does not require tumor biomarker testing, making it accessible to more patients without additional diagnostic procedures.
Together, these three trials provide oncologists with three distinct, evidence-based treatment pathways. The key insight is that these options are not ranked in a simple hierarchy. Instead, the best choice for each patient depends on their specific tumor characteristics, previous treatments, ability to tolerate certain drugs, and personal preferences.
The review emphasizes that successful treatment sequencing requires considering multiple clinical factors beyond just the primary trial results. These include whether patients previously received bevacizumab or PARP inhibitors (which affects what can be given next), whether patients can tolerate taxane chemotherapy drugs, individual risk for eye-related side effects (important for mirvetuximab), immune-related side effects (important for pembrolizumab), and corticosteroid requirements (relevant for relacorilant). The disease progression rate—how quickly the cancer is growing—also influences treatment timing and selection. Patient preferences and quality-of-life considerations are equally important in making treatment decisions.
Historically, platinum-resistant ovarian cancer was treated with non-platinum single-agent chemotherapy, sometimes with bevacizumab added based on a 2010 trial called AURELIA. However, this approach had significant limitations: short progression-free survival (the time before cancer progresses), limited durability of response (benefits didn’t last long), cumulative toxicity from repeated treatments, and no biological basis for selecting which patients would benefit. The three new trials represent a paradigm shift toward precision medicine, where treatment selection is based on specific tumor characteristics rather than a one-size-fits-all approach. This allows doctors to match patients with treatments most likely to work for their individual cancer.
As a narrative review rather than a new research study, this article synthesizes existing evidence but does not generate new data. The strength of conclusions depends on the quality of the underlying trials. The review does not establish a definitive treatment hierarchy, which some clinicians might find challenging when making real-world decisions. Additionally, the three trials may have enrolled somewhat different patient populations, making direct comparisons difficult. The review acknowledges that optimal treatment sequencing remains complex and requires individualized clinical judgment. Patients should discuss these options with their oncology team, as access to specific drugs may vary by location and insurance coverage.
The Bottom Line
For patients with platinum-resistant epithelial ovarian cancer: (1) Ask your oncologist whether your tumor can be tested for folate receptor alpha expression—if positive, mirvetuximab soravtansine is a strong option (high confidence). (2) Request PD-L1 testing if not already done—if positive, pembrolizumab plus paclitaxel is supported by evidence (high confidence). (3) Discuss relacorilant with nab-paclitaxel as an option that doesn’t require biomarker testing (moderate-to-high confidence). (4) Consider your prior treatments, ability to tolerate side effects, and personal priorities when choosing between options. These recommendations should be discussed with your oncology team, as individual circumstances vary.
These findings are most relevant for patients with platinum-resistant epithelial ovarian cancer (including fallopian tube and primary peritoneal cancer). Oncologists and cancer care teams should use this review to guide treatment selection and sequencing. Patients and families affected by these cancers should understand that new, more personalized treatment options are now available. Healthcare systems and policymakers should ensure access to biomarker testing and these newer treatment options. Patients with platinum-sensitive ovarian cancer or those still responding to platinum chemotherapy should continue with their current treatment plans, as this review focuses specifically on platinum-resistant disease.
Realistic expectations depend on which treatment is chosen and individual factors. Progression-free survival (time before cancer progresses) varies by treatment and patient characteristics but generally ranges from several months to over a year. Some patients may see tumor shrinkage within weeks, while others may take longer to respond. Side effects may appear within days to weeks of starting treatment. Discuss specific timeline expectations with your oncology team, as they can provide personalized estimates based on your tumor characteristics and medical history.
Frequently Asked Questions
What are the new treatment options for ovarian cancer that doesn’t respond to platinum chemotherapy?
Three new approaches are now available: mirvetuximab soravtansine for tumors with high folate receptor alpha, pembrolizumab plus paclitaxel for tumors with specific immune markers, and relacorilant with nab-paclitaxel without requiring biomarker testing. Your doctor can help determine which option is best for your specific situation.
Do I need biomarker testing to determine which treatment is right for me?
Biomarker testing (folate receptor alpha and PD-L1) helps identify which patients benefit most from mirvetuximab and pembrolizumab-based treatments. However, relacorilant with nab-paclitaxel is an option that doesn’t require biomarker testing. Discuss testing options with your oncology team.
How long do these new treatments work before the cancer progresses again?
Progression-free survival varies by treatment and individual factors, generally ranging from several months to over a year. The three trials showed improvements compared to historical treatments, but individual outcomes differ. Your oncologist can provide personalized estimates based on your tumor characteristics.
What side effects should I expect from these new ovarian cancer treatments?
Mirvetuximab may cause eye-related side effects; pembrolizumab can cause immune-related reactions; relacorilant may require corticosteroid management. All involve chemotherapy side effects. Discuss specific side effect risks and management strategies with your treatment team before starting.
Can these treatments be used in sequence if one stops working?
Yes, treatment sequencing is a key focus of this review. Doctors consider prior treatments, tumor characteristics, and individual factors when planning the order of treatments. Discuss sequencing strategies with your oncology team to understand what options may be available if your current treatment needs to change.
Want to Apply This Research?
- Track treatment response and side effects weekly: (1) Tumor marker levels if monitored by your doctor, (2) Imaging scan results and progression-free survival milestones, (3) Side effect severity (fatigue, nausea, eye problems, immune reactions) on a 1-10 scale, (4) Treatment dates and doses received, (5) Quality of life metrics (ability to work, exercise, daily activities).
- Work with your oncology team to: (1) Complete recommended biomarker testing (folate receptor alpha, PD-L1) before treatment selection, (2) Maintain a treatment journal documenting side effects and response, (3) Schedule regular follow-up appointments to assess treatment effectiveness, (4) Report new or worsening side effects immediately, (5) Discuss treatment sequencing options based on your specific tumor characteristics.
- Establish a long-term tracking system: (1) Monthly check-ins with your oncology team to assess response and side effects, (2) Imaging scans at intervals recommended by your doctor to measure tumor response, (3) Blood work to monitor tumor markers and overall health, (4) Documentation of treatment changes and reasons for sequencing decisions, (5) Regular quality-of-life assessments to ensure treatment aligns with your priorities and goals.
This article reviews clinical trial evidence for treating platinum-resistant epithelial ovarian cancer. It is intended for educational purposes and should not replace professional medical advice. Treatment decisions should be made in consultation with your oncology team, who can evaluate your individual tumor characteristics, medical history, and preferences. The availability of specific treatments may vary by location and insurance coverage. Clinical guidelines and treatment recommendations continue to evolve as new evidence emerges. Always discuss treatment options, benefits, risks, and sequencing strategies with your healthcare provider before making treatment decisions.
This research translation is published by Gram Research, the science division of Gram, an AI-powered nutrition tracking app.